Methylation pattern analysis in CpG islands of p15 and p16 tumor suppressor genes in pancreatic carcinoma tissue

World Chinese Journal of Digestology

Volumn 10, Issue 11, 2002, Pages 1264-1267

  Dong, Ke ^a   Li, Bo ^a   Qin, Yang ^a   Li, Cheng Zhi ^a   Liu, Jian Yu ^b   Sun, Zhi Lin ^a   Sun, Ze Fang ^a  

^a SICHUAN UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P15; PROTEIN P16;

ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CPG ISLAND; DIAGNOSTIC PROCEDURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; PANCREAS CARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION;

EID: 0036856941     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000;60:1835-1839
2. Gong YL, Xu GM, Huang WD, Chen LB. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol 2000;73:95-99
3. Chappuis PO, Ghadirian P, Foulkes WD. The role of genetic factors in the etiology of pancreatic adenocarcinoma: An update. Cancer Invest 2001;19:65-75
4. Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, Redston M, Gallinger S. Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000;60:409-416
5. Sorio C, Bonora A, Orlandini S, Moore PS, Capelli P, Cristofori P, Dal Negro G, Marchiori P, Gaviraghi G, Falconi M, Pederzoli P, Zamboni G, Scarpa A. Successful xenografting of cryopreserved primary pancreatic cancer. Virchows Arch 2001;438:154-158
6. Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 2001;8:89-92
7. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89:469-474
8. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-1266
9. Sato N, Ueki T, Fukushima N, Iacobuzio-Donahue CA, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002;123:365-372
10. Gerdes B, Ramaswamy A, Ziegler A, Lang SA, Kersting M, Baumann R, Wild A, Moll R, Rothmund M, Bartsch DK. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: An analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg 2002;235:51-59
11. Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M, Imai K. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001;61:3139-3144
12. Gerdes B, Ramaswamy A, Kersting M, Ernst M, Lang S, Schuermann M, Wild A, Bartsch DK. p16(INK4a) alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer. Surgery 2001;129:490-497
13. Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 2000;85:4146-4156
14. Gerdes B, Bartsch DK, Ramaswamy A, Kersting M, Wild A, Schuermann M, Frey M, Rothmund M. Multiple primary tumors as an indicator for p16INK4a germline mutations in pancreatic cancer patients? Pancreas 2000;21:369-375
15. Geradts J, Hruban RH, Schutte M, Kern SE, Maynard R. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 2000;8:71-79
16. sihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50:401-423
17. Qin Y, Li B, Tan YS, Sun ZL. Polymorphism of p16INK4a gene and rare mutation of p15INK4b gene exon2 in primary hepatocarcinoma. World J Gastroenterol 2000;6:411-414
18. Sach SI, Pyun HY. J-Aza-2-deoxycytidine leads to down regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. Cancer Letter 2000;160:81-88
19. Christina M, Martha M, Jones PA. Inhibition of DNA methylation by 5-Aza-2′-deoxytidine Suppress the grows of human tumor lines. Cancer Res 1998;58:95-101
20. Haspel J, Blanco C. Jeffrey J. Promoter Methylation Analysis on Micro-dissected Paraffin-Embedded tissues using bisulfite Treatment and PCR-SSCP. Biotechniques 1996;93:9821-9826
21. James G, Herman Jeremy R. Methylation-specific PCR: A novel PCR assay for methylation status of CPG islands. Proc Natl Acad. Sci. USA. Vo1;93.PP.9821-9826 September 1996 Medical Sciences.
22. Gonzalgo ML, Hayashiba T, Bender CM. The role of DNA methylation in exprssion of P19/P16 locus in human bladder cancer cell line. Cancer Res 1998;58:1245-1252
23. Matsuda Y, Ichida T. p16INK4 is inactivated by extensive CPG methylation in human hepatocellular carcinoma. Gastrocenterology 1999;116:394-400
24. Fanx, Inda MM, Tumon T, Castresana JS. Improvement of the methylation specific PCR technical conditions for the detection of p16 prometer hypermethylation in small amounts of tumor DNA. Oncol Rep 2002;9:181-183
25. 16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-3120